Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA
Cylaina E. Bird
Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA
Jeffrey I. Traylor
Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA
Diana D. Shi
Department of Radiation Oncology, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
Tarek Y. El Ahmadieh
Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA
Timothy E. Richardson
Department of Pathology, Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, University of Texas Health San Antonio, San Antonio, TX 75229, USA
Samuel K. McBrayer
Children’s Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Kalil G. Abdullah
Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA
Despite advances in understanding of the molecular pathogenesis of glioma, outcomes remain dismal. Developing successful treatments for glioma requires faithful in vivo disease modeling and rigorous preclinical testing. Murine models, including xenograft, syngeneic, and genetically engineered models, are used to study glioma-genesis, identify methods of tumor progression, and test novel treatment strategies. Since the discovery of highly recurrent isocitrate dehydrogenase (IDH) mutations in lower-grade gliomas, there is increasing emphasis on effective modeling of IDH mutant brain tumors. Improvements in preclinical models that capture the phenotypic and molecular heterogeneity of gliomas are critical for the development of effective new therapies. Herein, we explore the current status, advancements, and challenges with contemporary murine glioma models.
